Nutrition check may boost quality of life in pancreatic cancer
NCT ID NCT06090916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether screening for malnutrition and providing weekly nutritional support can improve quality of life for people with pancreatic cancer that cannot be removed by surgery. About 100 adults with this type of cancer are taking part. The goal is to see if better nutrition can help with symptoms like weight loss, weakness, and pain, and possibly reduce hospital stays.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2023
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Unresectable pancreatic adenocarcinoma, receiving either 1) no chemotherapy, 2) 1st cycle of chemotherapy, or 3) greater than 1 cycle of chemotherapy if the patient's prognosis is greater than 6 months as determined by oncology collaborators * Life expectancy of greater than 3 months and a Karnofsky performance score of 60 or more * Adults \>= 18 years old male or female Exclusion Criteria: * Ascites requiring paracentesis for symptom improvement * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values greater than 5 times the upper limit of normal * Creatinine value greater than 2.0 for men and 1.5 for women * Uncontrolled pain * Uncontrolled nausea and vomiting
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma non-resectable are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental combo targets Hard-to-Treat GI cancers
- New drug combo trial for tough pancreatic cancer shows early promise
- New drug cocktail shows promise against Hard-to-Treat cancers
- Implantable pump fires chemo straight at pancreatic cancer
- New scan could reveal hidden oxygen levels in pancreatic cancer
- Can chemo before surgery make pancreatic cancer removable?